| EYEPOINT INC. DL-,01 |
| USA |
| Gesundheit |
| US30233G2093 / A2QJRU |
| PV3B (Frankfurt) / EYPT (NASDAQ) |
| FRA:PV3B, ETR:PV3B, PV3B:GR, NASDAQ:EYPT |
| - |
| https://eyepointpharma.co.. |
|
EyePoint, Inc. Common Stock represents equity in EyePoint, Inc., a biopharmaceutical company focused on developing and commercializing therapies for serious retinal diseases. The company’s current portfolio centers on ophthalmology products and sus..
>Volltext.. |
| 240.86 Mio. EUR |
| 102.65 Mio. EUR |
| 2.48 Mio. EUR |
| -279.72 Mio. EUR |
| -272.83 Mio. EUR |
| -3.33 EUR |
| 19.9 Mio. EUR |
| 98.28 Mio. EUR |
| -237.83 Mio. EUR |
| 4.3 |
| -94.46% |
| -80.34% |
| - |
| - |
| - |
| - |
| EYEPOINT |
| 19.10.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|